Białaczka włochatokomórkowa oporna na standardowÄ terapię analogiem puryn - opis przypadku i przeglÄ d piśmiennictwa

We present a case of a 64-year-old man who was treated with rituximab after second progression of HCL. In March 2011, rituximab was given at a dose of 375 mg/m2 i.v. once a week for eight weeks, with result of achievement of PR. During the last hospitalization in March 2013 the persistence of PR was confirmed.